Thomas Vanzieleghem, Ph.D.
About Thomas Vanzieleghem, Ph.D.
Thomas Vanzieleghem, Ph.D., is a Project Manager in R&D Proton Therapy at IBA, with a background in bioengineering and microbiology. He has extensive experience in project management and has contributed to the development of medical products and quality systems in the healthcare sector.
Work at IBA
Thomas Vanzieleghem serves as a Project Manager in Research and Development for Proton Therapy at IBA. He has held this position since 2020, contributing to advancements in proton therapy technology. His role involves overseeing projects that aim to enhance the efficacy and safety of proton therapy treatments. IBA is known for its innovative solutions in cancer treatment, and Vanzieleghem's expertise plays a significant part in the company's ongoing research initiatives.
Education and Expertise
Thomas Vanzieleghem earned a Master in Bioengineering from Université catholique de Louvain, where he studied Chemistry and Bio industries from 2005 to 2010. He furthered his education at the same institution, obtaining a Doctor of Philosophy (PhD) in Microbiology - Bioengineering from 2010 to 2015. This extensive academic background provides him with a strong foundation in bioengineering and microbiology, essential for his roles in research and development within the medical field.
Background in R&D Management
Before joining IBA, Thomas Vanzieleghem worked as a Project Manager at MaSThercell, focusing on the development and manufacturing of cell and gene therapy products. His prior experience includes serving as R&D Manager at OneLIFE SA from 2015 to 2019, where he played a key role in the early development stages of the company, concentrating on hospital hygiene and infection prevention. He also held the position of Project Manager at Catalent Pharma Solutions for one year.
Achievements in Quality Systems
During his tenure at OneLife, Thomas Vanzieleghem successfully implemented an ISO13485:2016 quality system, which significantly enhanced the quality and safety of medical device reprocessing products. His contributions included the development of high-end cleaning products aimed at reducing infection risks in medical device reprocessing, demonstrating his commitment to improving healthcare standards through effective quality management.